for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Adaptimmune Therapeutics PLC - ADR

ADAP.OQ

Latest Trade

0.99USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.95

 - 

10.11

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.99
Open
--
Volume
--
3M AVG Volume
7.75
Today's High
--
Today's Low
--
52 Week High
10.11
52 Week Low
0.95
Shares Out (MIL)
630.67
Market Cap (MIL)
101.87
Forward P/E
-0.78
Dividend (Yield %)
--

Latest Developments

More

Adaptimmune Therapeutics PLC Files For Mixed Shelf Of Up To $400 Million

Adaptimmune And Noile-Immune Announce Pact To Develop Spear T-Cell Products For Cancer

New Executive Team Announced At Adaptimmune

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Adaptimmune Therapeutics PLC - ADR

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials, which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10.

Industry

Biotechnology & Drugs

Contact Info

60 Jubilee Avenue

+44.1235.430000

https://www.adaptimmune.com/

Executive Leadership

David M. Mott

Non-Executive Independent Chairman of the Board

Adrian Rawcliffe

Chief Executive Officer, Director

Michael R. Garone

Interim Chief Financial Officer

William C. Bertrand

Chief Operating Officer

John Lunger

Chief Patient Supply Officer

Key Stats

2.43 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.1K

2019(E)

0.0K
EPS (USD)

2016

-1.020

2017

-0.780

2018

-0.960

2019(E)

-1.235
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.40
Price To Book (MRQ)
0.54
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-52.30
Return on Equity (TTM)
-44.11

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up